Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

INDUSTRY 30 OTHER 19 UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Platinum-resistant Recurrent Ovarian Cancer 1

Interventions

Paclitaxel 20 Capecitabine 18 S 1 (combination) 17 Cisplatin 15 Oxaliplatin 11 apatinib 8 Radiotherapy, Intensity-Modulated 8 Epirubicin 8 Docetaxel 8 Carboplatin 8 Radiotherapy 7 Irinotecan 7 titanium silicide 6 sintilimab 6 pyrotinib 6 nimotuzumab 6 anlotinib 6 Albumin-Bound Paclitaxel 6 130-nm albumin-bound paclitaxel 6 nedaplatin 5 camrelizumab 5 Temozolomide 5 Etoposide 5 Drug Therapy 5 Bevacizumab 5 nabiximols 4 Vinorelbine 4 Trastuzumab 4 Radiation Dose Hypofractionation 4 Radiation 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

UNKNOWN × 1-dodecylpyridoxal × Clear all

NCT04348032 2022-03-31

APPROVE

ChineseAMS

Phase 2 Unknown

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡